Fulgent Genetics

Our mission is to develop flexible and affordable diagnostics and therapeutics that improve the everyday lives of those around us. Founded in 2011, Fulgent has evolved into a premier, full-service genomic testing company built around a foundational technology platform. Through our diverse testing menu, Fulgent is focused on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive health. We believe that by providing a wide range of effective, flexible testing options in conjunction with best-in-class service and support, we can redefine the way medicine is managed for patients and clinicians alike. - Our Products & Services...

Genetic testing,inherited disease,dna sequencing,panel testing,single gene testing,clia licensed,cap accredited,next gen sequencing,sanger sequencing,cancer testing,cancer panel,brca1,brca2,covid testing,clinical trial biomarker testing,companion diagnostics,patient screening and enrollment,genomics,transcriptomics,proteomics,single cell genomics and proteomics,spatial genomics and proteomics,pathology,and epigenomics

Fulgent genetics operates in the Biotechnology research industry.

Fulgent genetics's revenue is 101m - 500m

Fulgent genetics has 201 - 500 employees.